Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 6Recruiting 3Active not recruiting 2Unknown 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Neoplasms 1

Interventions

Specimen Handling 3Blood Specimen Collection 2somapacitan 1pembrolizumab 1ibrutinib 1gallium 68 PSMA-11 1fluorodopa F 18 1exemestane 1durvalumab 1Tumor Burden 1Telemedicine 1Tamoxifen 1Standard of Care 1Semen Analysis 1Radiography, Panoramic 1Protons 1Physical Examination 1Photons 1Music Therapy 1Magnetic Resonance Spectroscopy 1Letrozole 1JNJ-64619178 1JNJ-64264681 1High-Intensity Interval Training 1Exercise 1Esophagectomy 1Electrocardiography 1Community Health Workers 1Angptl4 protein, mouse 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Neoplasms × Letrozole × Clear all
NCT05645536 2026-01-12

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Tolmar Inc.

Phase 3 Enrolling by invitation
250 enrolled
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡